Latest news and press releases about Alto Neuroscience, Inc. (ANRO): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder.
Price
| Price | $30.00 |
| Market Cap | $1.1B |
| Exchange | NYSE |
| Country | US |
Valuation Ratios
| Price / Book | 5.27 |
| EV / EBITDA | -10.88 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -46.46% |
| Return on Invested Capital | 18.43% |
| Return on Assets | -33.16% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACIU · ALDX · AMRN · CLLS · CTNM · DBVT · DRTS
Explore sector: Healthcare · Biotechnology
More sections of ANRO: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks